PHILADELPHIA, PA -- (Marketwire) -- 08/19/09 -- Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, is scheduled to participate in the following upcoming investor conferences:

Event:   FTN Equity Capital Markets Health Care Corporate Access Conference
Date:    Wednesday, September 2, 2009
Time:    9:30 a.m. to 3:00 p.m. ET (Individual Meetings)
Place:   Grand Hyatt New York Hotel
         Park Avenue and Grand Central Station
         New York, N.Y.
Event:   Thomas Weisel Partners Health Care Conference 2009
Date:    Wednesday, September 9, 2009
Time:    3:00 p.m. ET (Presentation by Eurand Chairman and CEO
          Gearóid Faherty)
Place:   Four Seasons Hotel Boston
         200 Boylston Street
         Boston, Mass.

An audio webcast of the Company's presentation at the Thomas Weisel Partners Conference will be available by accessing the investor relations section of www.eurand.com and will be available via replay for 30 days following the date of the presentation.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had five products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.